Legal Representation
Attorney
Makiko Coffland
USPTO Deadlines
Next Deadline
25 days remaining
Non-Final Action Mailed
Due Date
November 27, 2025
Extension Available
Until February 27, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
11 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 15, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 14, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 14, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 14, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 27, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 27, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 27, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 27, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 30, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jun 30, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 30, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment and prevention of rare and orphan diseases and disorders; pharmaceutical preparations for the treatment and prevention of hematological diseases and disorders; pharmaceutical preparations for the treatment and prevention of inflammatory diseases and disorders; pharmaceutical preparations for the treatment and prevention of genetic diseases and disorders; pharmaceutical preparations for the treatment and prevention of hereditary angioedema (HAE); pharmaceutical preparations for the treatment and prevention of bradykinin mediated angioedema; pharmaceutical preparations for the treatment and prevention of acquired angioedema
Class 044
Providing medical information to healthcare providers and patients relating to hematological, inflammatory, genetic, and rare diseases and disorders; providing medical information, namely, providing healthcare providers and patients with information regarding clinical research, clinical trials and studies, disease management resources, and access to pharmaceuticals for the treatment and prevention of hereditary angioedema
Classification
International Classes
005
044